undamentalytics Newsletter
Sign in

Alaunos Therapeutics, Inc. income statement

In fiscal 2025, Alaunos Therapeutics, Inc. reported revenue of $5,000, down 50.0% on the year before, operating income of −$4.2m (a -84500.0% margin) and net income of −$4.2m, or −$2.20 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122016Dec 20162017Dec 20172018Dec 20182020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1171600030000
Research and development5783158453453502516012
General and administrative152014152028281312432
Operating income−71−102−165−53−54−80−78−35−34−5−4−4
Interest expense——————1320——
Income tax——————————0—
Net income−64−96−165−54−53−80−79−38−5−5−4−4
Diluted EPS−$145.50−$1.22−$1.32−$0.53$0.96−$57.00−$0.37−$26.10−$21.97−$2.92−$2.20−$1.80
Diluted shares (average)—————1m1m1m2m2m2m2m
EBITDA−71−102−165−53−53−79−75−32−32−5−4−4

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CELZ vs TCRTLYEL vs TCRTAIM vs TCRT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Alaunos Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alaunos Therapeutics, Inc.